Ingevity Corporation (NYSE:NGVT – Get Free Report) CEO David Li sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $75.83, for a total transaction of $379,150.00. Following the transaction, the chief executive officer owned 120,636 shares of the company’s stock, valued at approximately $9,147,827.88. This represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ingevity Price Performance
Ingevity stock traded down $1.78 during mid-day trading on Tuesday, reaching $74.01. The company had a trading volume of 177,777 shares, compared to its average volume of 291,037. Ingevity Corporation has a fifty-two week low of $45.85 and a fifty-two week high of $79.29. The company has a current ratio of 1.61, a quick ratio of 1.15 and a debt-to-equity ratio of 22.52. The company has a market cap of $2.54 billion, a P/E ratio of 50.34 and a beta of 1.16. The business has a fifty day simple moving average of $73.75 and a 200 day simple moving average of $71.72.
Ingevity (NYSE:NGVT – Get Free Report) last posted its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.41. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. The firm had revenue of $314.10 million for the quarter, compared to analysts’ expectations of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, equities research analysts predict that Ingevity Corporation will post 5.4 earnings per share for the current year.
Institutional Investors Weigh In On Ingevity
Wall Street Analyst Weigh In
NGVT has been the subject of a number of research reports. Wall Street Zen lowered shares of Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Weiss Ratings raised shares of Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Ingevity currently has a consensus rating of “Hold” and a consensus target price of $80.00.
View Our Latest Stock Report on NGVT
About Ingevity
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Further Reading
- Five stocks we like better than Ingevity
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
